Azimilide dihydrochloride (BioDeep_00000774289)

   


代谢物信息卡片


Azimilide (Dihydrochloride)

化学式: C23H30Cl3N5O3 (529.1414120000001)
中文名称: 盐酸阿齐利特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)N=CC3=CC=C(O3)C4=CC=C(C=C4)Cl.Cl.Cl
InChI: 2*1H/b25-16+

描述信息

C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker

同义名列表

2 个代谢物同义名

Azimilide (Dihydrochloride); Azimilide dihydrochloride



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Leif Carlsson, Denis Chartier, Stanley Nattel. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. Journal of cardiovascular pharmacology. 2006 Jan; 47(1):123-32. doi: 10.1097/01.fjc.0000196242.04384.c3. [PMID: 16424796]
  • P Riley, P C Figary, J R Entwisle, A L Roe, G A Thompson, R Ohashi, N Ohashi, T J Moorehead. The metabolic profile of azimilide in man: in vivo and in vitro evaluations. Journal of pharmaceutical sciences. 2005 Sep; 94(9):2084-95. doi: 10.1002/jps.20429. [PMID: 16052551]
  • Roger D Toothaker, Alfred E Corey, Suzanne N Valentine, Jeff R Agnew, Nikhil Parekh, Werner Moehrke, Gary A Thompson, James H Powell. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. Journal of clinical pharmacology. 2005 Jul; 45(7):773-80. doi: 10.1177/0091270005276948. [PMID: 15951467]
  • Mohamed El Mouelhi, Dan J Worley, Barbara Kuzmak, Anthony J Destefano, Gary A Thompson. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. British journal of clinical pharmacology. 2004 Dec; 58(6):641-7. doi: 10.1111/j.1365-2125.2004.02222.x. [PMID: 15563362]
  • Alfred E Corey, Jeffrey R Agnew, Eileen C King, Nikhil J Parekh, James H Powell, Gary A Thompson. Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration. Journal of pharmaceutical sciences. 2004 May; 93(5):1279-86. doi: 10.1002/jps.20060. [PMID: 15067704]
  • Mohamed El Mouelhi, Dan J Worley, Barbara Kuzmak, Anthony J Destefano, Gary A Thompson. Influence of azimilide on CYP2C19-mediated metabolism. Journal of clinical pharmacology. 2004 Apr; 44(4):373-8. doi: 10.1177/0091270004263469. [PMID: 15051744]
  • Alfred E Corey, Jeffrey R Agnew, Suzanne N Valentine, Nikhil J Parekh, James H Powell, Gary A Thompson. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. British journal of clinical pharmacology. 2002 Nov; 54(5):449-52. doi: 10.1046/j.1365-2125.2002.01664.x. [PMID: 12445022]
  • R R Brooks, S F Pong, N J Izzo, T J Moorehead, M Gopalakrishnan, D J Triggle. Interaction of azimilide with neurohumoral and channel receptors. Biochemical pharmacology. 2001 Oct; 62(7):883-92. doi: 10.1016/s0006-2952(01)00737-7. [PMID: 11543723]
  • L Phillips, T H Grasela, J R Agnew, E A Ludwig, G A Thompson. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clinical pharmacology and therapeutics. 2001 Oct; 70(4):370-83. doi: . [PMID: 11673753]
  • A E Corey, J R Agnew, S N Valentine, J D Nesbitt, D L Wagner, J H Powell, G A Thompson. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. Journal of clinical pharmacology. 1999 Dec; 39(12):1272-6. doi: 10.1177/00912709922012088. [PMID: 10586393]
  • A Corey, J Agnew, J Brum, N Parekh, S Valentine, M Williams. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride. Journal of clinical pharmacology. 1999 Dec; 39(12):1263-71. doi: 10.1177/00912709922012079. [PMID: 10586392]
  • X Q Qi, D Newman, P Dorian. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 1999 Mar; 3(1):61-7. doi: 10.1023/a:1009879708404. [PMID: 10354978]
  • A Corey, J Agnew, J Bao, P Bryson, P Comer, S Griffith, J Li. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. Journal of clinical pharmacology. 1997 Oct; 37(10):946-53. doi: 10.1002/j.1552-4604.1997.tb04269.x. [PMID: 9505986]
  • T Herzer, C A Wagner, S Waldegger, F Lang, A E Busch. Effect of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). European journal of pharmacology. 1995 Oct; 291(2):205-8. doi: 10.1016/0922-4106(95)90144-2. [PMID: 8566172]